Kathryn C B Tan1, Ching-Lung Cheung2, Alan C H Lee3, Joanne K Y Lam1, Ying Wong3, Sammy W M Shiu3. 1. Department of Medicine, University of Hong Kong, Hong Kong, China and kcbtan@hku.hk. 2. Department of Pharmacology and Pharmacy, University of Hong Kong, Hong Kong, China. 3. Department of Medicine, University of Hong Kong, Hong Kong, China and.
Abstract
BACKGROUND AND OBJECTIVES: Protein carbamylation is a consequence of uremia and carbamylated lipoproteins contribute to atherogenesis in CKD. Proteins can also be carbamylated by a urea-independent mechanism, and whether carbamylated lipoproteins contribute to the progression of CKD has not been investigated. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A case-control study was performed to determine whether there were changes in plasma levels of carbamylated lipoproteins in individuals with type 2 diabetes with eGFR >60 ml/min per 1.73 m2 compared with a group of age- and sex-matched healthy controls. A cohort of 1320 patients with type 2 diabetes with baseline eGFR ≥30 ml/min per 1.73 m2 was longitudinally followed up to evaluate the association between carbamylated lipoproteins and progression of CKD. The primary kidney outcome was defined as doubling of serum creatinine and/or initiation of KRT during follow-up. Plasma carbamylated LDLs and HDLs was measured by ELISA. RESULTS: In individuals with diabetes with eGFR >60 ml/min per 1.73 m2, both plasma carbamylated LDL and HDL levels were higher compared with healthy controls (P<0.001). After a mean follow-up of 9 years of the diabetic cohort, individuals in the top quartile of carbamylated LDL (hazard ratio, 2.21; 95% confidence interval, 1.42 to 3.46; P<0.001) and carbamylated HDL (hazard ratio, 4.53; 95% confidence interval, 2.87 to 7.13; P<0.001) had higher risk of deterioration of kidney function compared with those in the lowest quartile. On multivariable Cox regression analysis, plasma carbamylated LDL was no longer associated with kidney outcome after adjusting for baseline eGFR and potential confounding factors. However, the association between plasma carbamylated HDL and kidney outcome remained significant and was independent of HDL cholesterol. CONCLUSIONS: Plasma carbamylated HDL but not carbamylated LDL was independently associated with progression of CKD in patients with type 2 diabetes.
BACKGROUND AND OBJECTIVES: Protein carbamylation is a consequence of uremia and carbamylated lipoproteins contribute to atherogenesis in CKD. Proteins can also be carbamylated by a urea-independent mechanism, and whether carbamylated lipoproteins contribute to the progression of CKD has not been investigated. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A case-control study was performed to determine whether there were changes in plasma levels of carbamylated lipoproteins in individuals with type 2 diabetes with eGFR >60 ml/min per 1.73 m2 compared with a group of age- and sex-matched healthy controls. A cohort of 1320 patients with type 2 diabetes with baseline eGFR ≥30 ml/min per 1.73 m2 was longitudinally followed up to evaluate the association between carbamylated lipoproteins and progression of CKD. The primary kidney outcome was defined as doubling of serum creatinine and/or initiation of KRT during follow-up. Plasma carbamylated LDLs and HDLs was measured by ELISA. RESULTS: In individuals with diabetes with eGFR >60 ml/min per 1.73 m2, both plasma carbamylated LDL and HDL levels were higher compared with healthy controls (P<0.001). After a mean follow-up of 9 years of the diabetic cohort, individuals in the top quartile of carbamylated LDL (hazard ratio, 2.21; 95% confidence interval, 1.42 to 3.46; P<0.001) and carbamylated HDL (hazard ratio, 4.53; 95% confidence interval, 2.87 to 7.13; P<0.001) had higher risk of deterioration of kidney function compared with those in the lowest quartile. On multivariable Cox regression analysis, plasma carbamylated LDL was no longer associated with kidney outcome after adjusting for baseline eGFR and potential confounding factors. However, the association between plasma carbamylated HDL and kidney outcome remained significant and was independent of HDL cholesterol. CONCLUSIONS: Plasma carbamylated HDL but not carbamylated LDL was independently associated with progression of CKD in patients with type 2 diabetes.
Authors: Robert A Koeth; Kamyar Kalantar-Zadeh; Zeneng Wang; Xiaoming Fu; W H Wilson Tang; Stanley L Hazen Journal: J Am Soc Nephrol Date: 2013-02-21 Impact factor: 10.121
Authors: Sammy W M Shiu; Su-Mei Xiao; Ying Wong; Wing-Sun Chow; Karen S L Lam; Kathryn C B Tan Journal: Clin Sci (Lond) Date: 2014-01 Impact factor: 6.124
Authors: A Baragetti; G D Norata; C Sarcina; F Rastelli; L Grigore; K Garlaschelli; P Uboldi; I Baragetti; C Pozzi; A L Catapano Journal: J Intern Med Date: 2013-05-11 Impact factor: 8.989
Authors: Kathryn C B Tan; Ching-Lung Cheung; Alan C H Lee; Joanne K Y Lam; Ying Wong; Sammy W M Shiu Journal: Diabetologia Date: 2018-02-07 Impact factor: 10.122
Authors: Jia Teng Sun; Ke Yang; Lin Lu; Zheng Bin Zhu; Jin Zhou Zhu; Jing Wei Ni; Hui Han; Nan Chen; Rui Yan Zhang Journal: Am J Physiol Renal Physiol Date: 2016-01-13
Authors: Jamie Morton; Sophia Zoungas; Qiang Li; Anushka A Patel; John Chalmers; Mark Woodward; David S Celermajer; Joline W J Beulens; Ronald P Stolk; Paul Glasziou; Martin K C Ng Journal: Diabetes Care Date: 2012-08-13 Impact factor: 19.112
Authors: Sahir Kalim; Anders H Berg; Subbian Ananth Karumanchi; Ravi Thadhani; Andrew S Allegretti; Sagar Nigwekar; Sophia Zhao; Anand Srivastava; Dominic Raj; Rajat Deo; Anne Frydrych; Jing Chen; James Sondheimer; Tariq Shafi; Matthew Weir; James P Lash Journal: Nephrol Dial Transplant Date: 2021-12-31 Impact factor: 7.186
Authors: Zhongli Chen; Song Ding; Yan Ping Wang; Liang Chen; Jing Yan Mao; Ying Yang; Jia Teng Sun; Ke Yang Journal: J Transl Med Date: 2020-12-03 Impact factor: 5.531